Venture Life Group Plc · LSE:VLG
Venture Life — H1 2024 Earnings Presentation
17 slides from Venture Life's earnings presentation, September 2024
Slide 1: The partner of choice for self-care products
The partner [ of choice for self-care products Venture Life Group plc [ Interim Results 2021 and update on Acquisitions FY24 Interim Results September 2024 September 2021
Slide 2: Disclaimer
This document (the "Presentation") is being provided to a limited number of parties who have previously expressed an interest in acquiring an interest (the "Investor Interest") in Venture Life Group plc (the "Company"). If you are in any doubt about the investment to which the Presentation relates,
Slide 3: H1 24 highlights
Marketing investment fueling growth of VLG’s Brands and delivering strong cash generation H1 24 highlights VLG Brand revenue Gross margin Net cash from Operations +8% +90bps +58% Marketing spend Free cash flow Net leverage +93% +69% 1.09x (Dec 2023: 1.30x) 3
Slide 4: Commercial highlights
Increased awareness of VLG’s Brands across all key channels Commercial highlights VLG Power Brands Revenues No.1 Balance Activ is UK’s no.1 by both Value & Volume +35% +71% Balance Active growth in Pharmacy channel +20% Increase in Lift ‘brand awareness’ +14% +29 New listings gone live across UK ret
Slide 5: Performance by therapy areas
VLG’s Brands delivered 17% growth* in H1-24 (*excl. oncology support) Performance by therapy areas Energy Ear, Nose & VLG Brands Management Women's Health Throat Oral Care Footcare VLG Brands (excl. Gelclair) Customer Brands H124 vs H123 27% 14% 21% 1% 25% 8% 17% -9% * Oncology support revenues (Gel
Slide 6: Therapy highlights – UK & EU Retail: Energy Management
Energy Management (+27% growth) Therapy highlights – UK & EU Retail Energy Management • Lift Fast Acting Glucose Shots +35% YoY, Lift +35% 10 total +41% in online sales and +79% in Pharmacy largely from CPI. Lift YoY growth Lift new listings in • Lift AEB gaining ground in Grocery, listing Pharmacy
Slide 7: Therapy highlights UK & EU Retail (continued): Women's Health
Women’s Health (+13% growth) Therapy highlights UK & EU Retail (continued) Women’s Health Pharmacy PLOFs “UK’s No.1 BV treatment” both in volume +71% 12 and value Pharmacy growth New listings across • Grocery (+41% YoY) and Pharmacy (+71% YoY) driving YoY channels in H1 the growth. • Thrush cream co
Slide 8: Therapy highlights UK & EU Retail (continued): Ear, Nose & Throat
Ear, Nose & Throat (+16% growth) Therapy highlights UK & EU Retail (continued) ENT “UK’s No.1 ear wax removal spray” +73% 5 • Earol Olive Spray winning again the Natural Healthcare category for 2024 MVP Award Pharmacy growth new listings in H1 YoY • Strong in store off-shelf activation in Boots for
Slide 9: Therapy highlights UK & EU Retail (continued): Oral Care
Oral Care (+3% growth) Therapy highlights UK & EU Retail (continued) Oral Care • Oral Care coming back to growth thanks to better frequency of promotions and further listings +43% 7 Pharmacy • Amazon benefitting from promotional activity, Online growth YoY new listings across delivering an impressiv
Slide 10: UK and EU Commercial Results – new listings and losses in H1
UK and EU Commercial Results – delivering a total of 29 new listings and 6 losses in H1 BRANDS H1 2024 H2 2024 Launch of Thrush cream in April ‘24 Launch of Thrush cream in Feb ‘24 Launch of Thrush cream in Sep ‘24 Launch of Thrush cream and filled gaps of existing Balance Launch of Moisture range a
Slide 11: UK and EU – Summary H1 highlights, H2 priorities
UK and EU – SUMMARY H1 HIGHLIGHTS, H2 PRIORITIES H1 ’24 HIGHLIGHTS Launch of AEB in Sainsbury’s where we have half of shelf presence in the Boots off shelf in Feb-Mar ‘24 Expanded Balance Activ presence in “Energy” fixture with Lift overall Rollout of Earol baby in Pharmacy contributing positively t
Slide 12: International VLG Brand highlights
Increasing geographic reach across Europe and USA International VLG Brand highlights 6 New long-term partnering agreements signed £1.0m Value of ‘first orders’ from these agreements 1 New collaboration signed with an existing blue-chip partner to develop new products 1 Agreement in principle reached
Slide 13: Financial highlights
Deleveraging progress on track resulting from strong cash generation Financial highlights Revenue £m VLG Brands Revenue £m Revenue Mix Gross Profit £m 10.0 41. 0% 9.0 40.0% 23.5 23.5 8.9 41% 8.7 8.0 13.9 47% 45% 39 . 0% 12.9 56% 61% 7.0 7.7 18.9 38.0% 6.0 5.0 37 . 0% 10.1 13.9 4.0 5.0 4.9 13.7 36 .
Slide 14: Margin performance
Gross margin continuing to improve since supply chain issues faced in H2-22 Margin performance Gross margin recovery on track following the Investment in marketing and commercial team fuelling VLG height of supply chain issues in H2-22 Brands growth 40.3% 26.8% 38.1% 36.5% 36.8% 24.8% 35.6% 23.6% 23
Slide 15: Corporate development
Strive for sustainable growth both commercially and environmentally Corporate development Operational improvement Sustainability rating retained Internalisation of Earol manufacture delivering margin and working capital improvements Entity and group structure rationalisation on- course to streamline
Slide 16: Post-period & Outlook
More to expect in 2024 Post-period & Outlook Margin improvement from strong H2 revenues comprising higher margin VLG Brands focus NPD pipeline delivering Menopause range and expansion of Earol product portfolio Active leverage reduction resulting from strong cash generation Operational efficiencies
Slide 17: Q&A
Q&A